speb/financial-data huggingface dataset:
NOVARTIND.NS income_statement (annual, 2024-03-31) — Selling And Marketing Expense: 158700000.00
NOVARTIND.NS income_statement (annual, 2024-03-31) — Selling General And Administration: 226500000.00
NOVARTIND.NS balance_sheet (annual, 2024-03-31) — Share Issued: 24690797.00
NOVARTIND.NS income_statement (annual, 2024-03-31) — Special Income Charges: 35500000.00
NOVARTIND.NS cash_flow (annual, 2024-03-31) — Stock Based Compensation: 2500000.00
NOVARTIND.NS balance_sheet (annual, 2024-03-31) — Stockholders Equity: 7448200000.00
NOVARTIND.NS balance_sheet (annual, 2024-03-31) — Tangible Book Value: 7448200000.00
NOVARTIND.NS income_statement (annual, 2024-03-31) — Tax Effect Of Unusual Items: 10880617.06
NOVARTIND.NS income_statement (annual, 2024-03-31) — Tax Provision: 376500000.00
NOVARTIND.NS income_statement (annual, 2024-03-31) — Tax Rate For Calcs: 0.31
NOVARTIND.NS cash_flow (annual, 2024-03-31) — Taxes Refund Paid: 382700000.00
NOVARTIND.NS balance_sheet (annual, 2024-03-31) — Total Assets: 9249300000.00
NOVARTIND.NS balance_sheet (annual, 2024-03-31) — Total Capitalization: 7448200000.00
NOVARTIND.NS balance_sheet (annual, 2024-03-31) — Total Debt: 69700000.00
NOVARTIND.NS balance_sheet (annual, 2024-03-31) — Total Equity Gross Minority Interest: 7448200000.00
NOVARTIND.NS income_statement (annual, 2024-03-31) — Total Expenses: 2687800000.00
NOVARTIND.NS balance_sheet (annual, 2024-03-31) — Total Liabilities Net Minority Interest: 1801100000.00
NOVARTIND.NS balance_sheet (annual, 2024-03-31) — Total Non Current Assets: 2256800000.00
NOVARTIND.NS balance_sheet (annual, 2024-03-31) — Total Non Current Liabilities Net Minority Interest: 229100000.00
NOVARTIND.NS balance_sheet (annual, 2024-03-31) — Total Tax Payable: 74800000.00
NOVARTIND.NS income_statement (annual, 2024-03-31) — Total Unusual Items: 35500000.00
NOVARTIND.NS income_statement (annual, 2024-03-31) — Total Unusual Items Excluding Goodwill: 35500000.00
NOVARTIND.NS balance_sheet (annual, 2024-03-31) — Treasury Shares Number: 0.00
NOVARTIND.NS balance_sheet (annual, 2024-03-31) — Working Capital: 5420600000.00
NOVARTIND.NS income_statement (annual, 2024-03-31) — Write Off: 1700000.00
NOVARTIND.NS balance_sheet (quarterly, 2024-09-30) — Accounts Payable: 401000000.00
NOVARTIND.NS balance_sheet (quarterly, 2024-09-30) — Accounts Receivable: 381100000.00
NOVARTIND.NS balance_sheet (quarterly, 2024-09-30) — Available For Sale Securities: 13100000.00
NOVARTIND.NS balance_sheet (quarterly, 2024-09-30) — Capital Lease Obligations: 60300000.00
NOVARTIND.NS balance_sheet (quarterly, 2024-09-30) — Capital Stock: 123400000.00
NOVARTIND.NS balance_sheet (quarterly, 2024-09-30) — Cash And Cash Equivalents: 210700000.00
NOVARTIND.NS balance_sheet (quarterly, 2024-09-30) — Cash Cash Equivalents And Short Term Investments: 5976800000.00
NOVARTIND.NS balance_sheet (quarterly, 2024-09-30) — Common Stock: 123400000.00
NOVARTIND.NS balance_sheet (quarterly, 2024-09-30) — Common Stock Equity: 7292400000.00
NOVARTIND.NS balance_sheet (quarterly, 2024-09-30) — Current Assets: 6953200000.00
NOVARTIND.NS balance_sheet (quarterly, 2024-09-30) — Current Capital Lease Obligation: 19500000.00
NOVARTIND.NS balance_sheet (quarterly, 2024-09-30) — Current Debt: 0.00
NOVARTIND.NS balance_sheet (quarterly, 2024-09-30) — Current Debt And Capital Lease Obligation: 19500000.00
NOVARTIND.NS balance_sheet (quarterly, 2024-09-30) — Current Liabilities: 1402200000.00
NOVARTIND.NS balance_sheet (quarterly, 2024-09-30) — Current Provisions: 594800000.00
NOVARTIND.NS balance_sheet (quarterly, 2024-09-30) — Gross PPE: 56300000.00
NOVARTIND.NS balance_sheet (quarterly, 2024-09-30) — Inventory: 335800000.00
NOVARTIND.NS balance_sheet (quarterly, 2024-09-30) — Invested Capital: 7292400000.00
NOVARTIND.NS balance_sheet (quarterly, 2024-09-30) — Investmentin Financial Assets: 13100000.00
NOVARTIND.NS balance_sheet (quarterly, 2024-09-30) — Long Term Capital Lease Obligation: 40800000.00
NOVARTIND.NS balance_sheet (quarterly, 2024-09-30) — Long Term Debt And Capital Lease Obligation: 40800000.00
NOVARTIND.NS balance_sheet (quarterly, 2024-09-30) — Long Term Provisions: 171300000.00
NOVARTIND.NS balance_sheet (quarterly, 2024-09-30) — Net PPE: 56300000.00
NOVARTIND.NS balance_sheet (quarterly, 2024-09-30) — Net Tangible Assets: 7292400000.00
NOVARTIND.NS balance_sheet (quarterly, 2024-09-30) — Non Current Deferred Taxes Assets: 166300000.00
NOVARTIND.NS balance_sheet (quarterly, 2024-09-30) — Ordinary Shares Number: 24690797.00
NOVARTIND.NS balance_sheet (quarterly, 2024-09-30) — Other Current Assets: 259500000.00
NOVARTIND.NS balance_sheet (quarterly, 2024-09-30) — Other Current Liabilities: 24500000.00
NOVARTIND.NS balance_sheet (quarterly, 2024-09-30) — Other Equity Interest: 7169000000.00
NOVARTIND.NS balance_sheet (quarterly, 2024-09-30) — Other Non Current Assets: 606200000.00
NOVARTIND.NS balance_sheet (quarterly, 2024-09-30) — Other Properties: 56300000.00
NOVARTIND.NS balance_sheet (quarterly, 2024-09-30) — Other Short Term Investments: 5766100000.00
NOVARTIND.NS balance_sheet (quarterly, 2024-09-30) — Payables: 542100000.00
NOVARTIND.NS balance_sheet (quarterly, 2024-09-30) — Share Issued: 24690797.00
NOVARTIND.NS balance_sheet (quarterly, 2024-09-30) — Stockholders Equity: 7292400000.00
NOVARTIND.NS balance_sheet (quarterly, 2024-09-30) — Tangible Book Value: 7292400000.00
NOVARTIND.NS balance_sheet (quarterly, 2024-09-30) — Total Assets: 8909100000.00
NOVARTIND.NS balance_sheet (quarterly, 2024-09-30) — Total Capitalization: 7292400000.00
NOVARTIND.NS balance_sheet (quarterly, 2024-09-30) — Total Debt: 60300000.00
NOVARTIND.NS balance_sheet (quarterly, 2024-09-30) — Total Equity Gross Minority Interest: 7292400000.00
NOVARTIND.NS balance_sheet (quarterly, 2024-09-30) — Total Liabilities Net Minority Interest: 1616700000.00
NOVARTIND.NS balance_sheet (quarterly, 2024-09-30) — Total Non Current Assets: 1955900000.00
NOVARTIND.NS balance_sheet (quarterly, 2024-09-30) — Total Non Current Liabilities Net Minority Interest: 214500000.00
NOVARTIND.NS balance_sheet (quarterly, 2024-09-30) — Total Tax Payable: 141100000.00
NOVARTIND.NS balance_sheet (quarterly, 2024-09-30) — Working Capital: 5551000000.00
NOVARTIND.NS income_statement (quarterly, 2024-12-31) — +Operating Expense: 174500000.00
NOVARTIND.NS income_statement (quarterly, 2024-12-31) — +Total Revenue: 930000000.00
NOVARTIND.NS income_statement (quarterly, 2024-12-31) — Cost Of Revenue: 504600000.00
NOVARTIND.NS income_statement (quarterly, 2024-12-31) — Depreciation And Amortization In Income Statement: 5300000.00
NOVARTIND.NS income_statement (quarterly, 2024-12-31) — Depreciation Income Statement: 5300000.00
NOVARTIND.NS income_statement (quarterly, 2024-12-31) — Diluted NI Availto Com Stockholders: 254500000.00
NOVARTIND.NS income_statement (quarterly, 2024-12-31) — EBIT: 356500000.00
NOVARTIND.NS income_statement (quarterly, 2024-12-31) — EBITDA: 361800000.00
NOVARTIND.NS income_statement (quarterly, 2024-12-31) — Gross Profit: 425400000.00
NOVARTIND.NS income_statement (quarterly, 2024-12-31) — Interest Expense: 3600000.00
NOVARTIND.NS income_statement (quarterly, 2024-12-31) — Interest Expense Non Operating: 3600000.00
NOVARTIND.NS income_statement (quarterly, 2024-12-31) — Net Income: 254500000.00
NOVARTIND.NS income_statement (quarterly, 2024-12-31) — Net Income Common Stockholders: 254500000.00
NOVARTIND.NS income_statement (quarterly, 2024-12-31) — Net Income Continuous Operations: 254500000.00
NOVARTIND.NS income_statement (quarterly, 2024-12-31) — Net Income From Continuing And Discontinued Operation: 254500000.00
NOVARTIND.NS income_statement (quarterly, 2024-12-31) — Net Income From Continuing Operation Net Minority Interest: 254500000.00
NOVARTIND.NS income_statement (quarterly, 2024-12-31) — Net Income Including Noncontrolling Interests: 254500000.00
NOVARTIND.NS income_statement (quarterly, 2024-12-31) — Net Interest Income: -3600000.00
NOVARTIND.NS income_statement (quarterly, 2024-12-31) — Net Non Operating Interest Income Expense: -3600000.00
NOVARTIND.NS income_statement (quarterly, 2024-12-31) — Normalized EBITDA: 362200000.00
NOVARTIND.NS income_statement (quarterly, 2024-12-31) — Normalized Income: 254788466.99
NOVARTIND.NS income_statement (quarterly, 2024-12-31) — Operating Income: 250900000.00
NOVARTIND.NS income_statement (quarterly, 2024-12-31) — Operating Revenue: 930000000.00
NOVARTIND.NS income_statement (quarterly, 2024-12-31) — Other Non Operating Income Expenses: 106000000.00
NOVARTIND.NS income_statement (quarterly, 2024-12-31) — Other Operating Expenses: 121100000.00
NOVARTIND.NS income_statement (quarterly, 2024-12-31) — Otherunder Preferred Stock Dividend: 0.00
NOVARTIND.NS income_statement (quarterly, 2024-12-31) — Pretax Income: 352900000.00
NOVARTIND.NS income_statement (quarterly, 2024-12-31) — Reconciled Cost Of Revenue: 504600000.00
NOVARTIND.NS income_statement (quarterly, 2024-12-31) — Reconciled Depreciation: 5300000.00
NOVARTIND.NS income_statement (quarterly, 2024-12-31) — Special Income Charges: -400000.00
NOVARTIND.NS income_statement (quarterly, 2024-12-31) — Tax Effect Of Unusual Items: -111533.01
NOVARTIND.NS income_statement (quarterly, 2024-12-31) — Tax Provision: 98400000.00
NOVARTIND.NS income_statement (quarterly, 2024-12-31) — Tax Rate For Calcs: 0.28
NOVARTIND.NS income_statement (quarterly, 2024-12-31) — Total Expenses: 679100000.00
NOVARTIND.NS income_statement (quarterly, 2024-12-31) — Total Unusual Items: -400000.00
NOVARTIND.NS income_statement (quarterly, 2024-12-31) — Total Unusual Items Excluding Goodwill: -400000.00
NOVARTIND.NS income_statement (quarterly, 2024-12-31) — Write Off: 400000.00
NOVARTIND.NS income_statement (annual, 2025-03-31) — +Operating Expense: 589900000.00
NOVARTIND.NS income_statement (quarterly, 2025-03-31) — +Operating Expense: 114000000.00
NOVARTIND.NS income_statement (annual, 2025-03-31) — +Total Revenue: 3562700000.00
NOVARTIND.NS income_statement (quarterly, 2025-03-31) — +Total Revenue: 838800000.00
NOVARTIND.NS balance_sheet (annual, 2025-03-31) — Accounts Payable: 514700000.00
NOVARTIND.NS balance_sheet (quarterly, 2025-03-31) — Accounts Payable: 514700000.00
NOVARTIND.NS balance_sheet (annual, 2025-03-31) — Accounts Receivable: 401400000.00
NOVARTIND.NS balance_sheet (quarterly, 2025-03-31) — Accounts Receivable: 401400000.00
NOVARTIND.NS balance_sheet (annual, 2025-03-31) — Accumulated Depreciation: -28200000.00
NOVARTIND.NS balance_sheet (quarterly, 2025-03-31) — Accumulated Depreciation: -28200000.00
NOVARTIND.NS balance_sheet (annual, 2025-03-31) — Additional Paid In Capital: 36400000.00
NOVARTIND.NS balance_sheet (quarterly, 2025-03-31) — Additional Paid In Capital: 36400000.00
NOVARTIND.NS balance_sheet (annual, 2025-03-31) — Allowance For Doubtful Accounts Receivable: -23300000.00
NOVARTIND.NS balance_sheet (quarterly, 2025-03-31) — Allowance For Doubtful Accounts Receivable: -23300000.00
NOVARTIND.NS balance_sheet (annual, 2025-03-31) — Available For Sale Securities: 1600000.00
NOVARTIND.NS balance_sheet (quarterly, 2025-03-31) — Available For Sale Securities: 1600000.00
NOVARTIND.NS income_statement (annual, 2025-03-31) — Basic Average Shares: 24688035.00
NOVARTIND.NS income_statement (quarterly, 2025-03-31) — Basic Average Shares: 24684078.00
NOVARTIND.NS income_statement (annual, 2025-03-31) — Basic EPS: 40.87
NOVARTIND.NS income_statement (quarterly, 2025-03-31) — Basic EPS: 11.87
NOVARTIND.NS cash_flow (annual, 2025-03-31) — Beginning Cash Position: 449600000.00
NOVARTIND.NS balance_sheet (annual, 2025-03-31) — Buildings And Improvements: 73600000.00
NOVARTIND.NS balance_sheet (quarterly, 2025-03-31) — Buildings And Improvements: 73600000.00
NOVARTIND.NS balance_sheet (annual, 2025-03-31) — Capital Lease Obligations: 50600000.00
NOVARTIND.NS balance_sheet (quarterly, 2025-03-31) — Capital Lease Obligations: 50600000.00
NOVARTIND.NS balance_sheet (annual, 2025-03-31) — Capital Stock: 123400000.00
NOVARTIND.NS balance_sheet (quarterly, 2025-03-31) — Capital Stock: 123400000.00
NOVARTIND.NS balance_sheet (annual, 2025-03-31) — Cash And Cash Equivalents: 520700000.00
NOVARTIND.NS balance_sheet (quarterly, 2025-03-31) — Cash And Cash Equivalents: 520700000.00
NOVARTIND.NS balance_sheet (annual, 2025-03-31) — Cash Cash Equivalents And Short Term Investments: 6370700000.00
NOVARTIND.NS balance_sheet (quarterly, 2025-03-31) — Cash Cash Equivalents And Short Term Investments: 6370700000.00
NOVARTIND.NS cash_flow (annual, 2025-03-31) — Cash Dividends Paid: -617300000.00
NOVARTIND.NS balance_sheet (annual, 2025-03-31) — Cash Equivalents: 490000000.00
NOVARTIND.NS balance_sheet (quarterly, 2025-03-31) — Cash Equivalents: 490000000.00
NOVARTIND.NS balance_sheet (annual, 2025-03-31) — Cash Financial: 30700000.00
NOVARTIND.NS balance_sheet (quarterly, 2025-03-31) — Cash Financial: 30700000.00
NOVARTIND.NS cash_flow (annual, 2025-03-31) — Change In Inventory: 37500000.00
NOVARTIND.NS cash_flow (annual, 2025-03-31) — Change In Other Current Assets: 134100000.00
NOVARTIND.NS cash_flow (annual, 2025-03-31) — Change In Other Current Liabilities: -89810000.00
NOVARTIND.NS cash_flow (annual, 2025-03-31) — Change In Payable: -92500000.00
NOVARTIND.NS cash_flow (annual, 2025-03-31) — Change In Receivables: 15000000.00
NOVARTIND.NS cash_flow (annual, 2025-03-31) — Change In Working Capital: -7610000.00
NOVARTIND.NS cash_flow (annual, 2025-03-31) — Changes In Cash: 71100000.00
NOVARTIND.NS balance_sheet (annual, 2025-03-31) — Common Stock: 123400000.00
NOVARTIND.NS balance_sheet (quarterly, 2025-03-31) — Common Stock: 123400000.00
NOVARTIND.NS balance_sheet (annual, 2025-03-31) — Common Stock Equity: 7849600000.00
NOVARTIND.NS balance_sheet (quarterly, 2025-03-31) — Common Stock Equity: 7849600000.00
NOVARTIND.NS income_statement (annual, 2025-03-31) — Cost Of Revenue: 2028200000.00
NOVARTIND.NS income_statement (quarterly, 2025-03-31) — Cost Of Revenue: 493000000.00
NOVARTIND.NS balance_sheet (annual, 2025-03-31) — Current Assets: 7458200000.00
NOVARTIND.NS balance_sheet (quarterly, 2025-03-31) — Current Assets: 7458200000.00
NOVARTIND.NS balance_sheet (annual, 2025-03-31) — Current Capital Lease Obligation: 18500000.00
NOVARTIND.NS balance_sheet (quarterly, 2025-03-31) — Current Capital Lease Obligation: 18500000.00
NOVARTIND.NS balance_sheet (annual, 2025-03-31) — Current Debt: 0.00
NOVARTIND.NS balance_sheet (quarterly, 2025-03-31) — Current Debt: 0.00
NOVARTIND.NS balance_sheet (annual, 2025-03-31) — Current Debt And Capital Lease Obligation: 18500000.00
NOVARTIND.NS balance_sheet (quarterly, 2025-03-31) — Current Debt And Capital Lease Obligation: 18500000.00
NOVARTIND.NS balance_sheet (annual, 2025-03-31) — Current Liabilities: 1420500000.00
NOVARTIND.NS balance_sheet (quarterly, 2025-03-31) — Current Liabilities: 1420500000.00
NOVARTIND.NS balance_sheet (annual, 2025-03-31) — Current Provisions: 265000000.00
NOVARTIND.NS balance_sheet (quarterly, 2025-03-31) — Current Provisions: 265000000.00
NOVARTIND.NS cash_flow (annual, 2025-03-31) — Depreciation: 21900000.00
NOVARTIND.NS cash_flow (annual, 2025-03-31) — Depreciation And Amortization: 21900000.00
NOVARTIND.NS income_statement (annual, 2025-03-31) — Depreciation And Amortization In Income Statement: 21900000.00
NOVARTIND.NS income_statement (quarterly, 2025-03-31) — Depreciation And Amortization In Income Statement: 5300000.00
NOVARTIND.NS income_statement (annual, 2025-03-31) — Depreciation Income Statement: 21900000.00
NOVARTIND.NS income_statement (quarterly, 2025-03-31) — Depreciation Income Statement: 5300000.00
NOVARTIND.NS income_statement (annual, 2025-03-31) — Diluted Average Shares: 24688035.00
NOVARTIND.NS income_statement (quarterly, 2025-03-31) — Diluted Average Shares: 24684078.00
NOVARTIND.NS income_statement (annual, 2025-03-31) — Diluted EPS: 40.87
NOVARTIND.NS income_statement (quarterly, 2025-03-31) — Diluted EPS: 11.87
NOVARTIND.NS income_statement (annual, 2025-03-31) — Diluted NI Availto Com Stockholders: 1009000000.00
NOVARTIND.NS income_statement (quarterly, 2025-03-31) — Diluted NI Availto Com Stockholders: 293000000.00
NOVARTIND.NS balance_sheet (annual, 2025-03-31) — Dividends Payable: 20600000.00
NOVARTIND.NS balance_sheet (quarterly, 2025-03-31) — Dividends Payable: 20600000.00
NOVARTIND.NS income_statement (annual, 2025-03-31) — EBIT: 1311900000.00
NOVARTIND.NS income_statement (quarterly, 2025-03-31) — EBIT: 340100000.00
NOVARTIND.NS income_statement (annual, 2025-03-31) — EBITDA: 1333800000.00
NOVARTIND.NS income_statement (quarterly, 2025-03-31) — EBITDA: 345400000.00
NOVARTIND.NS cash_flow (annual, 2025-03-31) — End Cash Position: 520700000.00
NOVARTIND.NS cash_flow (annual, 2025-03-31) — Financing Cash Flow: -641500000.00
NOVARTIND.NS balance_sheet (annual, 2025-03-31) — Finished Goods: 411100000.00
NOVARTIND.NS balance_sheet (quarterly, 2025-03-31) — Finished Goods: 411100000.00
NOVARTIND.NS cash_flow (annual, 2025-03-31) — Free Cash Flow: 745700000.00
NOVARTIND.NS cash_flow (annual, 2025-03-31) — Gain Loss On Sale Of PPE: -1100000.00
NOVARTIND.NS income_statement (annual, 2025-03-31) — General And Administrative Expense: 41600000.00
NOVARTIND.NS balance_sheet (annual, 2025-03-31) — Gross Accounts Receivable: 424700000.00
NOVARTIND.NS balance_sheet (quarterly, 2025-03-31) — Gross Accounts Receivable: 424700000.00
NOVARTIND.NS balance_sheet (annual, 2025-03-31) — Gross PPE: 73600000.00
NOVARTIND.NS balance_sheet (quarterly, 2025-03-31) — Gross PPE: 73600000.00
NOVARTIND.NS income_statement (annual, 2025-03-31) — Gross Profit: 1534500000.00
NOVARTIND.NS income_statement (quarterly, 2025-03-31) — Gross Profit: 345800000.00
NOVARTIND.NS income_statement (annual, 2025-03-31) — Interest Expense: 7700000.00
NOVARTIND.NS income_statement (quarterly, 2025-03-31) — Interest Expense: 1200000.00
NOVARTIND.NS income_statement (annual, 2025-03-31) — Interest Expense Non Operating: 7700000.00
NOVARTIND.NS income_statement (quarterly, 2025-03-31) — Interest Expense Non Operating: 1200000.00
NOVARTIND.NS income_statement (annual, 2025-03-31) — Interest Income: 409500000.00
NOVARTIND.NS income_statement (annual, 2025-03-31) — Interest Income Non Operating: 409500000.00
NOVARTIND.NS cash_flow (annual, 2025-03-31) — Interest Paid Cff: -100000.00
NOVARTIND.NS cash_flow (annual, 2025-03-31) — Interest Received Cfi: 412700000.00
NOVARTIND.NS balance_sheet (annual, 2025-03-31) — Inventory: 411100000.00
NOVARTIND.NS balance_sheet (quarterly, 2025-03-31) — Inventory: 411100000.00
NOVARTIND.NS balance_sheet (annual, 2025-03-31) — Invested Capital: 7849600000.00
NOVARTIND.NS balance_sheet (quarterly, 2025-03-31) — Invested Capital: 7849600000.00
NOVARTIND.NS cash_flow (annual, 2025-03-31) — Investing Cash Flow: -33100000.00
NOVARTIND.NS balance_sheet (annual, 2025-03-31) — Investmentin Financial Assets: 1600000.00
NOVARTIND.NS balance_sheet (quarterly, 2025-03-31) — Investmentin Financial Assets: 1600000.00
NOVARTIND.NS balance_sheet (annual, 2025-03-31) — Long Term Capital Lease Obligation: 32100000.00
NOVARTIND.NS balance_sheet (quarterly, 2025-03-31) — Long Term Capital Lease Obligation: 32100000.00
NOVARTIND.NS balance_sheet (annual, 2025-03-31) — Long Term Debt And Capital Lease Obligation: 32100000.00
NOVARTIND.NS balance_sheet (quarterly, 2025-03-31) — Long Term Debt And Capital Lease Obligation: 32100000.00
NOVARTIND.NS balance_sheet (annual, 2025-03-31) — Long Term Provisions: 173900000.00
NOVARTIND.NS balance_sheet (quarterly, 2025-03-31) — Long Term Provisions: 173900000.00
NOVARTIND.NS balance_sheet (annual, 2025-03-31) — Machinery Furniture Equipment: 0.00
NOVARTIND.NS balance_sheet (quarterly, 2025-03-31) — Machinery Furniture Equipment: 0.00
NOVARTIND.NS cash_flow (annual, 2025-03-31) — Net Foreign Currency Exchange Gain Loss: -3200000.00
NOVARTIND.NS income_statement (annual, 2025-03-31) — Net Income: 1009000000.00
NOVARTIND.NS income_statement (quarterly, 2025-03-31) — Net Income: 293000000.00
NOVARTIND.NS income_statement (annual, 2025-03-31) — Net Income Common Stockholders: 1009000000.00
NOVARTIND.NS income_statement (quarterly, 2025-03-31) — Net Income Common Stockholders: 293000000.00
NOVARTIND.NS income_statement (annual, 2025-03-31) — Net Income Continuous Operations: 1009000000.00
NOVARTIND.NS income_statement (quarterly, 2025-03-31) — Net Income Continuous Operations: 293000000.00
NOVARTIND.NS income_statement (annual, 2025-03-31) — Net Income From Continuing And Discontinued Operation: 1009000000.00
NOVARTIND.NS income_statement (quarterly, 2025-03-31) — Net Income From Continuing And Discontinued Operation: 293000000.00
NOVARTIND.NS income_statement (annual, 2025-03-31) — Net Income From Continuing Operation Net Minority Interest: 1009000000.00
NOVARTIND.NS income_statement (quarterly, 2025-03-31) — Net Income From Continuing Operation Net Minority Interest: 293000000.00
NOVARTIND.NS cash_flow (annual, 2025-03-31) — Net Income From Continuing Operations: 1304200000.00
NOVARTIND.NS income_statement (annual, 2025-03-31) — Net Income Including Noncontrolling Interests: 1009000000.00
NOVARTIND.NS income_statement (quarterly, 2025-03-31) — Net Income Including Noncontrolling Interests: 293000000.00
NOVARTIND.NS income_statement (annual, 2025-03-31) — Net Interest Income: -7700000.00
NOVARTIND.NS income_statement (quarterly, 2025-03-31) — Net Interest Income: -1200000.00
NOVARTIND.NS cash_flow (annual, 2025-03-31) — Net Investment Purchase And Sale: -449000000.00
NOVARTIND.NS income_statement (annual, 2025-03-31) — Net Non Operating Interest Income Expense: -7700000.00
NOVARTIND.NS income_statement (quarterly, 2025-03-31) — Net Non Operating Interest Income Expense: -1200000.00
NOVARTIND.NS balance_sheet (annual, 2025-03-31) — Net PPE: 45400000.00
NOVARTIND.NS balance_sheet (quarterly, 2025-03-31) — Net PPE: 45400000.00
NOVARTIND.NS cash_flow (annual, 2025-03-31) — Net PPE Purchase And Sale: 3200000.00
NOVARTIND.NS balance_sheet (annual, 2025-03-31) — Net Tangible Assets: 7849600000.00
NOVARTIND.NS balance_sheet (quarterly, 2025-03-31) — Net Tangible Assets: 7849600000.00
NOVARTIND.NS balance_sheet (annual, 2025-03-31) — Non Current Deferred Taxes Assets: 154800000.00
NOVARTIND.NS balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Taxes Assets: 154800000.00
NOVARTIND.NS balance_sheet (annual, 2025-03-31) — Non Current Prepaid Assets: 1192900000.00
NOVARTIND.NS balance_sheet (quarterly, 2025-03-31) — Non Current Prepaid Assets: 1192900000.00
NOVARTIND.NS income_statement (annual, 2025-03-31) — Normalized EBITDA: 1385000000.00
NOVARTIND.NS income_statement (quarterly, 2025-03-31) — Normalized EBITDA: 343400000.00
NOVARTIND.NS income_statement (annual, 2025-03-31) — Normalized Income: 1048611102.59
NOVARTIND.NS income_statement (quarterly, 2025-03-31) — Normalized Income: 291270876.36
NOVARTIND.NS cash_flow (annual, 2025-03-31) — Operating Cash Flow: 745700000.00
NOVARTIND.NS income_statement (annual, 2025-03-31) — Operating Income: 944600000.00
NOVARTIND.NS income_statement (quarterly, 2025-03-31) — Operating Income: 231800000.00
NOVARTIND.NS income_statement (annual, 2025-03-31) — Operating Revenue: 3562700000.00
NOVARTIND.NS income_statement (quarterly, 2025-03-31) — Operating Revenue: 838800000.00
NOVARTIND.NS balance_sheet (annual, 2025-03-31) — Ordinary Shares Number: 24690797.00
NOVARTIND.NS balance_sheet (quarterly, 2025-03-31) — Ordinary Shares Number: 24690797.00
NOVARTIND.NS balance_sheet (annual, 2025-03-31) — Other Current Assets: 156000000.00
NOVARTIND.NS balance_sheet (quarterly, 2025-03-31) — Other Current Assets: 156000000.00
NOVARTIND.NS balance_sheet (annual, 2025-03-31) — Other Current Liabilities: 34400000.00
NOVARTIND.NS balance_sheet (quarterly, 2025-03-31) — Other Current Liabilities: 34400000.00
NOVARTIND.NS balance_sheet (annual, 2025-03-31) — Other Equity Interest: 7726200000.00
NOVARTIND.NS balance_sheet (quarterly, 2025-03-31) — Other Equity Interest: 7726200000.00
NOVARTIND.NS cash_flow (annual, 2025-03-31) — Other Non Cash Items: -407300000.00
NOVARTIND.NS balance_sheet (annual, 2025-03-31) — Other Non Current Assets: 656600000.00
NOVARTIND.NS balance_sheet (quarterly, 2025-03-31) — Other Non Current Assets: 656600000.00
NOVARTIND.NS income_statement (annual, 2025-03-31) — Other Non Operating Income Expenses: 418500000.00
NOVARTIND.NS income_statement (quarterly, 2025-03-31) — Other Non Operating Income Expenses: 106300000.00
NOVARTIND.NS income_statement (annual, 2025-03-31) — Other Operating Expenses: 380800000.00
NOVARTIND.NS income_statement (quarterly, 2025-03-31) — Other Operating Expenses: 77000000.00
NOVARTIND.NS balance_sheet (annual, 2025-03-31) — Other Payable: 188200000.00
NOVARTIND.NS balance_sheet (quarterly, 2025-03-31) — Other Payable: 188200000.00
NOVARTIND.NS balance_sheet (annual, 2025-03-31) — Other Properties: 35700000.00
NOVARTIND.NS balance_sheet (quarterly, 2025-03-31) — Other Properties: 35700000.00
NOVARTIND.NS balance_sheet (annual, 2025-03-31) — Other Receivables: 89000000.00
NOVARTIND.NS balance_sheet (quarterly, 2025-03-31) — Other Receivables: 89000000.00
NOVARTIND.NS balance_sheet (annual, 2025-03-31) — Other Short Term Investments: 5850000000.00
NOVARTIND.NS balance_sheet (quarterly, 2025-03-31) — Other Short Term Investments: 5850000000.00
NOVARTIND.NS income_statement (annual, 2025-03-31) — Other Special Charges: 52900000.00
NOVARTIND.NS income_statement (quarterly, 2025-03-31) — Other Special Charges: -5700000.00
NOVARTIND.NS income_statement (annual, 2025-03-31) — Otherunder Preferred Stock Dividend: 0.00
NOVARTIND.NS income_statement (quarterly, 2025-03-31) — Otherunder Preferred Stock Dividend: 0.00
NOVARTIND.NS balance_sheet (annual, 2025-03-31) — Payables: 857900000.00
NOVARTIND.NS balance_sheet (quarterly, 2025-03-31) — Payables: 857900000.00
NOVARTIND.NS balance_sheet (annual, 2025-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 258100000.00
NOVARTIND.NS balance_sheet (quarterly, 2025-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 258100000.00
NOVARTIND.NS balance_sheet (annual, 2025-03-31) — Prepaid Assets: 165400000.00
NOVARTIND.NS balance_sheet (quarterly, 2025-03-31) — Prepaid Assets: 165400000.00
NOVARTIND.NS income_statement (annual, 2025-03-31) — Pretax Income: 1304200000.00
NOVARTIND.NS income_statement (quarterly, 2025-03-31) — Pretax Income: 338900000.00
NOVARTIND.NS balance_sheet (annual, 2025-03-31) — Properties: 0.00
NOVARTIND.NS balance_sheet (quarterly, 2025-03-31) — Properties: 0.00
NOVARTIND.NS cash_flow (annual, 2025-03-31) — Provisionand Write Offof Assets: 100000.00
NOVARTIND.NS cash_flow (annual, 2025-03-31) — Purchase Of Investment: -11500000000.00
NOVARTIND.NS cash_flow (annual, 2025-03-31) — Purchase Of PPE: 0.00
NOVARTIND.NS income_statement (annual, 2025-03-31) — Reconciled Cost Of Revenue: 2028200000.00
NOVARTIND.NS income_statement (quarterly, 2025-03-31) — Reconciled Cost Of Revenue: 493000000.00
NOVARTIND.NS income_statement (annual, 2025-03-31) — Reconciled Depreciation: 21900000.00
NOVARTIND.NS income_statement (quarterly, 2025-03-31) — Reconciled Depreciation: 5300000.00
NOVARTIND.NS income_statement (annual, 2025-03-31) — Rent And Landing Fees: 700000.00
NOVARTIND.NS income_statement (annual, 2025-03-31) — Rent Expense Supplemental: 700000.00
NOVARTIND.NS balance_sheet (annual, 2025-03-31) — Restricted Cash: 20600000.00
NOVARTIND.NS balance_sheet (quarterly, 2025-03-31) — Restricted Cash: 20600000.00
NOVARTIND.NS balance_sheet (annual, 2025-03-31) — Retained Earnings: 7689800000.00
NOVARTIND.NS balance_sheet (quarterly, 2025-03-31) — Retained Earnings: 7689800000.00
NOVARTIND.NS cash_flow (annual, 2025-03-31) — Sale Of Investment: 11051000000.00
NOVARTIND.NS cash_flow (annual, 2025-03-31) — Sale Of PPE: 3200000.00
NOVARTIND.NS income_statement (annual, 2025-03-31) — Selling And Marketing Expense: 105800000.00
NOVARTIND.NS income_statement (annual, 2025-03-31) — Selling General And Administration: 147400000.00
NOVARTIND.NS balance_sheet (annual, 2025-03-31) — Share Issued: 24690797.00
NOVARTIND.NS balance_sheet (quarterly, 2025-03-31) — Share Issued: 24690797.00
NOVARTIND.NS income_statement (annual, 2025-03-31) — Special Income Charges: -51200000.00
NOVARTIND.NS income_statement (quarterly, 2025-03-31) — Special Income Charges: 2000000.00
NOVARTIND.NS cash_flow (annual, 2025-03-31) — Stock Based Compensation: 3300000.00
NOVARTIND.NS balance_sheet (annual, 2025-03-31) — Stockholders Equity: 7849600000.00
NOVARTIND.NS balance_sheet (quarterly, 2025-03-31) — Stockholders Equity: 7849600000.00
NOVARTIND.NS balance_sheet (annual, 2025-03-31) — Tangible Book Value: 7849600000.00
NOVARTIND.NS balance_sheet (quarterly, 2025-03-31) — Tangible Book Value: 7849600000.00
NOVARTIND.NS income_statement (annual, 2025-03-31) — Tax Effect Of Unusual Items: -11588897.41
NOVARTIND.NS income_statement (quarterly, 2025-03-31) — Tax Effect Of Unusual Items: 270876.36
NOVARTIND.NS income_statement (annual, 2025-03-31) — Tax Provision: 295200000.00
NOVARTIND.NS income_statement (quarterly, 2025-03-31) — Tax Provision: 45900000.00
NOVARTIND.NS income_statement (annual, 2025-03-31) — Tax Rate For Calcs: 0.23
NOVARTIND.NS income_statement (quarterly, 2025-03-31) — Tax Rate For Calcs: 0.14
NOVARTIND.NS cash_flow (annual, 2025-03-31) — Taxes Refund Paid: -162900000.00
NOVARTIND.NS balance_sheet (annual, 2025-03-31) — Total Assets: 9478100000.00
NOVARTIND.NS balance_sheet (quarterly, 2025-03-31) — Total Assets: 9478100000.00
NOVARTIND.NS balance_sheet (annual, 2025-03-31) — Total Capitalization: 7849600000.00
NOVARTIND.NS balance_sheet (quarterly, 2025-03-31) — Total Capitalization: 7849600000.00
NOVARTIND.NS balance_sheet (annual, 2025-03-31) — Total Debt: 50600000.00
NOVARTIND.NS balance_sheet (quarterly, 2025-03-31) — Total Debt: 50600000.00
NOVARTIND.NS balance_sheet (annual, 2025-03-31) — Total Equity Gross Minority Interest: 7849600000.00
NOVARTIND.NS balance_sheet (quarterly, 2025-03-31) — Total Equity Gross Minority Interest: 7849600000.00
NOVARTIND.NS income_statement (annual, 2025-03-31) — Total Expenses: 2618100000.00
NOVARTIND.NS income_statement (quarterly, 2025-03-31) — Total Expenses: 607000000.00
NOVARTIND.NS balance_sheet (annual, 2025-03-31) — Total Liabilities Net Minority Interest: 1628500000.00
NOVARTIND.NS balance_sheet (quarterly, 2025-03-31) — Total Liabilities Net Minority Interest: 1628500000.00
NOVARTIND.NS balance_sheet (annual, 2025-03-31) — Total Non Current Assets: 2019900000.00
NOVARTIND.NS balance_sheet (quarterly, 2025-03-31) — Total Non Current Assets: 2019900000.00
NOVARTIND.NS balance_sheet (annual, 2025-03-31) — Total Non Current Liabilities Net Minority Interest: 208000000.00
NOVARTIND.NS balance_sheet (quarterly, 2025-03-31) — Total Non Current Liabilities Net Minority Interest: 208000000.00
NOVARTIND.NS balance_sheet (annual, 2025-03-31) — Total Tax Payable: 134400000.00
NOVARTIND.NS balance_sheet (quarterly, 2025-03-31) — Total Tax Payable: 134400000.00
NOVARTIND.NS income_statement (annual, 2025-03-31) — Total Unusual Items: -51200000.00
NOVARTIND.NS income_statement (quarterly, 2025-03-31) — Total Unusual Items: 2000000.00
NOVARTIND.NS income_statement (annual, 2025-03-31) — Total Unusual Items Excluding Goodwill: -51200000.00
NOVARTIND.NS income_statement (quarterly, 2025-03-31) — Total Unusual Items Excluding Goodwill: 2000000.00
NOVARTIND.NS balance_sheet (annual, 2025-03-31) — Working Capital: 6037700000.00
NOVARTIND.NS balance_sheet (quarterly, 2025-03-31) — Working Capital: 6037700000.00
NOVARTIND.NS income_statement (annual, 2025-03-31) — Write Off: -1700000.00
NOVARTIND.NS income_statement (quarterly, 2025-03-31) — Write Off: -2000000.00
NOVARTIND.NS income_statement (quarterly, 2025-06-30) — +Operating Expense: 141000000.00
NOVARTIND.NS income_statement (quarterly, 2025-06-30) — +Total Revenue: 875500000.00
NOVARTIND.NS income_statement (quarterly, 2025-06-30) — Basic Average Shares: 24682752.00
NOVARTIND.NS income_statement (quarterly, 2025-06-30) — Basic EPS: 11.19
NOVARTIND.NS income_statement (quarterly, 2025-06-30) — Cost Of Revenue: 467700000.00
NOVARTIND.NS income_statement (quarterly, 2025-06-30) — Depreciation And Amortization In Income Statement: 5300000.00
NOVARTIND.NS income_statement (quarterly, 2025-06-30) — Depreciation Income Statement: 5300000.00
NOVARTIND.NS income_statement (quarterly, 2025-06-30) — Diluted Average Shares: 24682752.00
NOVARTIND.NS income_statement (quarterly, 2025-06-30) — Diluted EPS: 11.19
NOVARTIND.NS income_statement (quarterly, 2025-06-30) — Diluted NI Availto Com Stockholders: 276200000.00
NOVARTIND.NS income_statement (quarterly, 2025-06-30) — EBIT: 373200000.00
NOVARTIND.NS income_statement (quarterly, 2025-06-30) — EBITDA: 378500000.00
NOVARTIND.NS income_statement (quarterly, 2025-06-30) — Gross Profit: 407800000.00
NOVARTIND.NS income_statement (quarterly, 2025-06-30) — Interest Expense: 1000000.00
NOVARTIND.NS income_statement (quarterly, 2025-06-30) — Interest Expense Non Operating: 1000000.00
NOVARTIND.NS income_statement (quarterly, 2025-06-30) — Net Income: 276200000.00
NOVARTIND.NS income_statement (quarterly, 2025-06-30) — Net Income Common Stockholders: 276200000.00
NOVARTIND.NS income_statement (quarterly, 2025-06-30) — Net Income Continuous Operations: 276200000.00
NOVARTIND.NS income_statement (quarterly, 2025-06-30) — Net Income From Continuing And Discontinued Operation: 276200000.00
NOVARTIND.NS income_statement (quarterly, 2025-06-30) — Net Income From Continuing Operation Net Minority Interest: 276200000.00
NOVARTIND.NS income_statement (quarterly, 2025-06-30) — Net Income Including Noncontrolling Interests: 276200000.00
NOVARTIND.NS income_statement (quarterly, 2025-06-30) — Net Interest Income: -1000000.00
NOVARTIND.NS income_statement (quarterly, 2025-06-30) — Net Non Operating Interest Income Expense: -1000000.00
NOVARTIND.NS income_statement (quarterly, 2025-06-30) — Normalized EBITDA: 378200000.00
NOVARTIND.NS income_statement (quarterly, 2025-06-30) — Normalized Income: 275977377.75
NOVARTIND.NS income_statement (quarterly, 2025-06-30) — Operating Income: 266800000.00
NOVARTIND.NS income_statement (quarterly, 2025-06-30) — Operating Revenue: 875500000.00
NOVARTIND.NS income_statement (quarterly, 2025-06-30) — Other Non Operating Income Expenses: 106100000.00
NOVARTIND.NS income_statement (quarterly, 2025-06-30) — Other Operating Expenses: 82800000.00
NOVARTIND.NS income_statement (quarterly, 2025-06-30) — Otherunder Preferred Stock Dividend: 0.00
NOVARTIND.NS income_statement (quarterly, 2025-06-30) — Pretax Income: 372200000.00
NOVARTIND.NS income_statement (quarterly, 2025-06-30) — Reconciled Cost Of Revenue: 467700000.00
NOVARTIND.NS income_statement (quarterly, 2025-06-30) — Reconciled Depreciation: 5300000.00
NOVARTIND.NS income_statement (quarterly, 2025-06-30) — Special Income Charges: 300000.00
NOVARTIND.NS income_statement (quarterly, 2025-06-30) — Tax Effect Of Unusual Items: 77377.75
NOVARTIND.NS income_statement (quarterly, 2025-06-30) — Tax Provision: 96000000.00
NOVARTIND.NS income_statement (quarterly, 2025-06-30) — Tax Rate For Calcs: 0.26
NOVARTIND.NS income_statement (quarterly, 2025-06-30) — Total Expenses: 608700000.00
NOVARTIND.NS income_statement (quarterly, 2025-06-30) — Total Unusual Items: 300000.00
NOVARTIND.NS income_statement (quarterly, 2025-06-30) — Total Unusual Items Excluding Goodwill: 300000.00
NOVARTIND.NS income_statement (quarterly, 2025-06-30) — Write Off: -300000.00
NOVARTIND.NS income_statement (quarterly, 2025-09-30) — Basic Average Shares: 24689093.00
NOVARTIND.NS income_statement (quarterly, 2025-09-30) — Basic EPS: 9.81
NOVARTIND.NS income_statement (quarterly, 2025-09-30) — Diluted Average Shares: 24689093.00
NOVARTIND.NS income_statement (quarterly, 2025-09-30) — Diluted EPS: 9.81
NOVARTIND.NS income_statement (quarterly, 2025-12-31) — +Operating Expense: 151500000.00
NOVARTIND.NS income_statement (quarterly, 2025-12-31) — +Total Revenue: 859000000.00
NOVARTIND.NS income_statement (quarterly, 2025-12-31) — Basic Average Shares: 24677914.00
NOVARTIND.NS income_statement (quarterly, 2025-12-31) — Basic EPS: 6.52
NOVARTIND.NS income_statement (quarterly, 2025-12-31) — Cost Of Revenue: 489000000.00
NOVARTIND.NS income_statement (quarterly, 2025-12-31) — Depreciation And Amortization In Income Statement: 4800000.00
NOVARTIND.NS income_statement (quarterly, 2025-12-31) — Depreciation Income Statement: 4800000.00
NOVARTIND.NS income_statement (quarterly, 2025-12-31) — Diluted Average Shares: 24677914.00
NOVARTIND.NS income_statement (quarterly, 2025-12-31) — Diluted EPS: 6.52
NOVARTIND.NS income_statement (quarterly, 2025-12-31) — Diluted NI Availto Com Stockholders: 160900000.00
NOVARTIND.NS income_statement (quarterly, 2025-12-31) — EBIT: 306300000.00
NOVARTIND.NS income_statement (quarterly, 2025-12-31) — EBITDA: 311100000.00
NOVARTIND.NS income_statement (quarterly, 2025-12-31) — Gross Profit: 370000000.00
NOVARTIND.NS income_statement (quarterly, 2025-12-31) — Interest Expense: 9800000.00
NOVARTIND.NS income_statement (quarterly, 2025-12-31) — Interest Expense Non Operating: 9800000.00
NOVARTIND.NS income_statement (quarterly, 2025-12-31) — Net Income: 160900000.00
NOVARTIND.NS income_statement (quarterly, 2025-12-31) — Net Income Common Stockholders: 160900000.00
NOVARTIND.NS income_statement (quarterly, 2025-12-31) — Net Income Continuous Operations: 160900000.00
NOVARTIND.NS income_statement (quarterly, 2025-12-31) — Net Income From Continuing And Discontinued Operation: 160900000.00
NOVARTIND.NS income_statement (quarterly, 2025-12-31) — Net Income From Continuing Operation Net Minority Interest: 160900000.00
NOVARTIND.NS income_statement (quarterly, 2025-12-31) — Net Income Including Noncontrolling Interests: 160900000.00
NOVARTIND.NS income_statement (quarterly, 2025-12-31) — Net Interest Income: -9800000.00
NOVARTIND.NS income_statement (quarterly, 2025-12-31) — Net Non Operating Interest Income Expense: -9800000.00
NOVARTIND.NS income_statement (quarterly, 2025-12-31) — Normalized EBITDA: 310800000.00
NOVARTIND.NS income_statement (quarterly, 2025-12-31) — Normalized Income: 160690000.00
NOVARTIND.NS income_statement (quarterly, 2025-12-31) — Operating Income: 218500000.00
NOVARTIND.NS income_statement (quarterly, 2025-12-31) — Operating Revenue: 859000000.00
NOVARTIND.NS income_statement (quarterly, 2025-12-31) — Other Non Operating Income Expenses: 87500000.00
NOVARTIND.NS income_statement (quarterly, 2025-12-31) — Other Operating Expenses: 85300000.00
NOVARTIND.NS income_statement (quarterly, 2025-12-31) — Otherunder Preferred Stock Dividend: 0.00
NOVARTIND.NS income_statement (quarterly, 2025-12-31) — Pretax Income: 296500000.00
NOVARTIND.NS income_statement (quarterly, 2025-12-31) — Reconciled Cost Of Revenue: 489000000.00
NOVARTIND.NS income_statement (quarterly, 2025-12-31) — Reconciled Depreciation: 4800000.00
NOVARTIND.NS income_statement (quarterly, 2025-12-31) — Special Income Charges: 300000.00
NOVARTIND.NS income_statement (quarterly, 2025-12-31) — Tax Effect Of Unusual Items: 90000.00
NOVARTIND.NS income_statement (quarterly, 2025-12-31) — Tax Provision: 135600000.00
NOVARTIND.NS income_statement (quarterly, 2025-12-31) — Tax Rate For Calcs: 0.30
NOVARTIND.NS income_statement (quarterly, 2025-12-31) — Total Expenses: 640500000.00
NOVARTIND.NS income_statement (quarterly, 2025-12-31) — Total Unusual Items: 300000.00
NOVARTIND.NS income_statement (quarterly, 2025-12-31) — Total Unusual Items Excluding Goodwill: 300000.00
NOVARTIND.NS income_statement (quarterly, 2025-12-31) — Write Off: -300000.00
NOVARTIND.NS income_statement (annual, 2026-03-31) — +Operating Expense: 639400000.00
NOVARTIND.NS income_statement (quarterly, 2026-03-31) — +Operating Expense: 182400000.00
NOVARTIND.NS income_statement (annual, 2026-03-31) — +Total Revenue: 3543300000.00
NOVARTIND.NS income_statement (quarterly, 2026-03-31) — +Total Revenue: 905500000.00
NOVARTIND.NS balance_sheet (annual, 2026-03-31) — Accounts Payable: 546500000.00
NOVARTIND.NS balance_sheet (quarterly, 2026-03-31) — Accounts Payable: 546500000.00
NOVARTIND.NS balance_sheet (annual, 2026-03-31) — Accounts Receivable: 370500000.00
NOVARTIND.NS balance_sheet (quarterly, 2026-03-31) — Accounts Receivable: 370500000.00
NOVARTIND.NS balance_sheet (annual, 2026-03-31) — Available For Sale Securities: 10600000.00
NOVARTIND.NS balance_sheet (quarterly, 2026-03-31) — Available For Sale Securities: 10600000.00
NOVARTIND.NS income_statement (annual, 2026-03-31) — Basic Average Shares: 24689984.00
NOVARTIND.NS income_statement (quarterly, 2026-03-31) — Basic Average Shares: 24682307.00
NOVARTIND.NS income_statement (annual, 2026-03-31) — Basic EPS: 37.74
NOVARTIND.NS income_statement (quarterly, 2026-03-31) — Basic EPS: 10.23
NOVARTIND.NS cash_flow (annual, 2026-03-31) — Beginning Cash Position: 520700000.00
NOVARTIND.NS cash_flow (annual, 2026-03-31) — Capital Expenditure: -3400000.00
NOVARTIND.NS balance_sheet (annual, 2026-03-31) — Capital Lease Obligations: 32100000.00
NOVARTIND.NS balance_sheet (quarterly, 2026-03-31) — Capital Lease Obligations: 32100000.00
NOVARTIND.NS balance_sheet (annual, 2026-03-31) — Capital Stock: 123400000.00
NOVARTIND.NS balance_sheet (quarterly, 2026-03-31) — Capital Stock: 123400000.00
NOVARTIND.NS balance_sheet (annual, 2026-03-31) — Cash And Cash Equivalents: 525000000.00
NOVARTIND.NS balance_sheet (quarterly, 2026-03-31) — Cash And Cash Equivalents: 525000000.00
NOVARTIND.NS balance_sheet (annual, 2026-03-31) — Cash Cash Equivalents And Short Term Investments: 6683500000.00
NOVARTIND.NS balance_sheet (quarterly, 2026-03-31) — Cash Cash Equivalents And Short Term Investments: 6683500000.00
NOVARTIND.NS cash_flow (annual, 2026-03-31) — Cash Dividends Paid: -617300000.00
NOVARTIND.NS cash_flow (annual, 2026-03-31) — Change In Inventory: -122100000.00
NOVARTIND.NS cash_flow (annual, 2026-03-31) — Change In Other Current Assets: -20900000.00
NOVARTIND.NS cash_flow (annual, 2026-03-31) — Change In Other Current Liabilities: -10500000.00
NOVARTIND.NS cash_flow (annual, 2026-03-31) — Change In Payable: 21800000.00
NOVARTIND.NS cash_flow (annual, 2026-03-31) — Change In Receivables: 32200000.00
NOVARTIND.NS cash_flow (annual, 2026-03-31) — Change In Working Capital: -139100000.00
NOVARTIND.NS cash_flow (annual, 2026-03-31) — Changes In Cash: 4300000.00
NOVARTIND.NS balance_sheet (annual, 2026-03-31) — Common Stock: 123400000.00
NOVARTIND.NS balance_sheet (quarterly, 2026-03-31) — Common Stock: 123400000.00
NOVARTIND.NS balance_sheet (annual, 2026-03-31) — Common Stock Equity: 8178300000.00
NOVARTIND.NS balance_sheet (quarterly, 2026-03-31) — Common Stock Equity: 8178300000.00
NOVARTIND.NS income_statement (annual, 2026-03-31) — Cost Of Revenue: 1983700000.00
NOVARTIND.NS income_statement (quarterly, 2026-03-31) — Cost Of Revenue: 521800000.00
NOVARTIND.NS balance_sheet (annual, 2026-03-31) — Current Assets: 7682500000.00
NOVARTIND.NS balance_sheet (quarterly, 2026-03-31) — Current Assets: 7682500000.00
NOVARTIND.NS balance_sheet (annual, 2026-03-31) — Current Capital Lease Obligation: 16400000.00
NOVARTIND.NS balance_sheet (quarterly, 2026-03-31) — Current Capital Lease Obligation: 16400000.00
NOVARTIND.NS balance_sheet (annual, 2026-03-31) — Current Debt And Capital Lease Obligation: 16400000.00
NOVARTIND.NS balance_sheet (quarterly, 2026-03-31) — Current Debt And Capital Lease Obligation: 16400000.00
NOVARTIND.NS balance_sheet (annual, 2026-03-31) — Current Liabilities: 1449700000.00
NOVARTIND.NS balance_sheet (quarterly, 2026-03-31) — Current Liabilities: 1449700000.00
NOVARTIND.NS balance_sheet (annual, 2026-03-31) — Current Provisions: 500900000.00
NOVARTIND.NS balance_sheet (quarterly, 2026-03-31) — Current Provisions: 500900000.00
NOVARTIND.NS cash_flow (annual, 2026-03-31) — Depreciation: 19500000.00
NOVARTIND.NS cash_flow (annual, 2026-03-31) — Depreciation And Amortization: 19500000.00
NOVARTIND.NS income_statement (annual, 2026-03-31) — Depreciation And Amortization In Income Statement: 19500000.00
NOVARTIND.NS income_statement (quarterly, 2026-03-31) — Depreciation And Amortization In Income Statement: 4200000.00
NOVARTIND.NS income_statement (annual, 2026-03-31) — Depreciation Income Statement: 19500000.00
NOVARTIND.NS income_statement (quarterly, 2026-03-31) — Depreciation Income Statement: 4200000.00
NOVARTIND.NS income_statement (annual, 2026-03-31) — Diluted Average Shares: 24689984.00
NOVARTIND.NS income_statement (quarterly, 2026-03-31) — Diluted Average Shares: 24682307.00
NOVARTIND.NS income_statement (annual, 2026-03-31) — Diluted EPS: 37.74
NOVARTIND.NS income_statement (quarterly, 2026-03-31) — Diluted EPS: 10.23
NOVARTIND.NS income_statement (annual, 2026-03-31) — Diluted NI Availto Com Stockholders: 931800000.00
NOVARTIND.NS income_statement (quarterly, 2026-03-31) — Diluted NI Availto Com Stockholders: 252500000.00
NOVARTIND.NS income_statement (annual, 2026-03-31) — EBIT: 1309200000.00
NOVARTIND.NS income_statement (quarterly, 2026-03-31) — EBIT: 302100000.00
NOVARTIND.NS income_statement (annual, 2026-03-31) — EBITDA: 1328700000.00
NOVARTIND.NS income_statement (quarterly, 2026-03-31) — EBITDA: 306300000.00
NOVARTIND.NS cash_flow (annual, 2026-03-31) — End Cash Position: 525000000.00
NOVARTIND.NS cash_flow (annual, 2026-03-31) — Financing Cash Flow: -639300000.00
NOVARTIND.NS cash_flow (annual, 2026-03-31) — Free Cash Flow: 463900000.00
NOVARTIND.NS cash_flow (annual, 2026-03-31) — Gain Loss On Sale Of PPE: 300000.00
NOVARTIND.NS balance_sheet (annual, 2026-03-31) — Gross PPE: 28800000.00
NOVARTIND.NS balance_sheet (quarterly, 2026-03-31) — Gross PPE: 28800000.00
NOVARTIND.NS income_statement (annual, 2026-03-31) — Gross Profit: 1559600000.00
NOVARTIND.NS income_statement (quarterly, 2026-03-31) — Gross Profit: 383700000.00
NOVARTIND.NS income_statement (annual, 2026-03-31) — Interest Expense: 12600000.00
NOVARTIND.NS income_statement (quarterly, 2026-03-31) — Interest Expense: 700000.00
NOVARTIND.NS income_statement (annual, 2026-03-31) — Interest Expense Non Operating: 12600000.00
NOVARTIND.NS income_statement (quarterly, 2026-03-31) — Interest Expense Non Operating: 700000.00
NOVARTIND.NS income_statement (annual, 2026-03-31) — Interest Income: 13300000.00
NOVARTIND.NS income_statement (quarterly, 2026-03-31) — Interest Income: 13300000.00
NOVARTIND.NS income_statement (annual, 2026-03-31) — Interest Income Non Operating: 13300000.00
NOVARTIND.NS income_statement (quarterly, 2026-03-31) — Interest Income Non Operating: 13300000.00
NOVARTIND.NS cash_flow (annual, 2026-03-31) — Interest Paid Cff: 0.00
NOVARTIND.NS cash_flow (annual, 2026-03-31) — Interest Received Cfi: 379700000.00
NOVARTIND.NS balance_sheet (annual, 2026-03-31) — Inventory: 533200000.00
NOVARTIND.NS balance_sheet (quarterly, 2026-03-31) — Inventory: 533200000.00
NOVARTIND.NS balance_sheet (annual, 2026-03-31) — Invested Capital: 8178300000.00
NOVARTIND.NS balance_sheet (quarterly, 2026-03-31) — Invested Capital: 8178300000.00
NOVARTIND.NS cash_flow (annual, 2026-03-31) — Investing Cash Flow: 176300000.00
NOVARTIND.NS balance_sheet (annual, 2026-03-31) — Investmentin Financial Assets: 10600000.00
NOVARTIND.NS balance_sheet (quarterly, 2026-03-31) — Investmentin Financial Assets: 10600000.00
NOVARTIND.NS balance_sheet (annual, 2026-03-31) — Long Term Capital Lease Obligation: 15700000.00
NOVARTIND.NS balance_sheet (quarterly, 2026-03-31) — Long Term Capital Lease Obligation: 15700000.00
NOVARTIND.NS balance_sheet (annual, 2026-03-31) — Long Term Debt And Capital Lease Obligation: 15700000.00
NOVARTIND.NS balance_sheet (quarterly, 2026-03-31) — Long Term Debt And Capital Lease Obligation: 15700000.00
NOVARTIND.NS balance_sheet (annual, 2026-03-31) — Long Term Provisions: 137500000.00
NOVARTIND.NS balance_sheet (quarterly, 2026-03-31) — Long Term Provisions: 137500000.00
NOVARTIND.NS cash_flow (annual, 2026-03-31) — Net Foreign Currency Exchange Gain Loss: 14100000.00
NOVARTIND.NS income_statement (annual, 2026-03-31) — Net Income: 931800000.00
NOVARTIND.NS income_statement (quarterly, 2026-03-31) — Net Income: 252500000.00
NOVARTIND.NS income_statement (annual, 2026-03-31) — Net Income Common Stockholders: 931800000.00
NOVARTIND.NS income_statement (quarterly, 2026-03-31) — Net Income Common Stockholders: 252500000.00
NOVARTIND.NS income_statement (annual, 2026-03-31) — Net Income Continuous Operations: 931800000.00
NOVARTIND.NS income_statement (quarterly, 2026-03-31) — Net Income Continuous Operations: 252500000.00
NOVARTIND.NS income_statement (annual, 2026-03-31) — Net Income From Continuing And Discontinued Operation: 931800000.00
NOVARTIND.NS income_statement (quarterly, 2026-03-31) — Net Income From Continuing And Discontinued Operation: 252500000.00
NOVARTIND.NS income_statement (annual, 2026-03-31) — Net Income From Continuing Operation Net Minority Interest: 931800000.00